This aligns with evidence that IL-17A-neutralizing antibodies suppress CXCL5/CXCR2 axis activation in murine rosacea models, attenuating both inflammatory and fibrotic responses (Zhang C. et al., 2024). Here, CXCL5 is linked to rosacea.